+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute

Society for Immunotherapy of Cancer

The SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute is a two-day program and networking forum championed by SITC’s first female president, Lisa H. Butterfield, PhD.

Accepted applicants explore topics like gender equity, work-life balance, negotiation skills, team building and other leadership development strategies.

Apply today to network and share your experiences with emerging women leaders in cancer immunotherapy from clinical settings, industry, pharma, government and academia.

How To Organize Your Application

I. Applicant's Career Stage: In 50 words or less, please state your career stage relative to your terminal degree (for example: 2 years in current position, after a 3 year postdoc, which is 5 years since my PhD degree; or 2 years in current position after a 3 year residency in internal medicine and 3 years of oncology subspecialty training which is 8 years since my MD degree; or 5 years in my current position after completion of my PharmD, MBA, etc.)

II. Applicant's Statement of Benefit: In 50 words or less, please state why your career development would benefit from attending this event.

III. Proof of Student / Fellow Status: Proof of student/fellow status or years out from such status can be provided through a letter or transcript from the institution at which the applicant completed this work.

Selection Criteria

Selection is made by the SITC WIN Leadership Institute Program Co-Organizers. Applicants will be notified via email of their application’s acceptance or decline.

Program Co-Organizers will consider the following in their selection of applicants:

Career stage
Written responses to short answer questions

Priority will be given to applicants who are early in their independent professional careers or who are re-entering the workforce.

While not a requirement, SITC membership and participation in SITC programs or opportunities will be considered during the review process. Membership is a requirement for travel award applicants.

AI Based Application Success Predictor

At present, SITC does not publish a formal set of quantitative success predictors (e.g., scoring rubrics, priority weightings) for its fellowship or award programs — at least not in publicly accessible evaluation guidelines comparable to major funding agencies.

Instead, SITC funding decisions generally reflect standard peer assessment and eligibility criteria, such as:

✅ Alignment With Career Stage and Mission

Applicants must fit program requirements (e.g., early-career status, relevance to immunotherapy research) and demonstrate a commitment to advancing the field.

✅ Scientific & Clinical Relevance

For fellowships, projects or training plans that clearly advance cancer immunotherapy science or clinical application tend to be implicitly prioritized — though formal scoring metrics are not published.

✅ Membership & Eligibility Compliance

Many awards require applicants be current SITC members in good standing, and provide required documentation (CV, mentor information, letters).

✅ Peer Evaluation

Fellowship and award selections are typically made by committees familiar with cancer immunotherapy science; strong proposals tend to show potential impact, rigor, and feasibility — even though numerical scoring rubrics may not be public.

📌 Key Takeaways

SITC does provide financial support and recognition through fellowships and young investigator/award programs aimed at advancing careers in cancer immunotherapy research.

Formal public “grant success predictors” (like scoring rubrics) are not currently published by SITC in the same way that large research funders do.

Implicit factors that likely contribute to success include:

Relevance of training or research to immunotherapy

Early-career investigator status and mentor support

Clear alignment with SITC goals of advancing cancer immunotherapy science

Meeting eligibility and application requirements (e.g., membership).

Specialties

Cancer

Oncology

Immunology

Eligibility Requirements

This program is open to female applicants only. Applicants must currently work in the field of cancer immunotherapy or be interested in starting a career in the field. If you have attended past WIN programs, you are not eligible to apply.

In addition, applicants must fit one of the following criteria:

Five or fewer years since applicant’s post-doctoral PhD and/or MD experience (e.g., post-doctoral lab experience or medical residency/fellowship)
Ten or fewer years since applicant received terminal degree (PharmD, MBA, etc.)
Applicant is starting or in consideration for their first leadership position

Sponsor Details

Sponsor Institute/Organizations: Society for Immunotherapy of Cancer

Sponsor Type: Corporate/Non-Profit

Address: 555 East Wells Street, Suite 1100 | Milwaukee, WI | 53202-3823

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity